---
title: "First Tracks Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295709002.md"
datetime: "2026-08-12T20:57:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295709002.md)
  - [en](https://longbridge.com/en/news/295709002.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295709002.md)
generator: "portal-rs"
---

# First Tracks Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.95.

EBIT: As of FY2026 Q2, the actual value is USD -34.94 M.

The provided reference indicates that First Tracks Biotherapeutics, Inc. issued a press release on August 12, 2026, detailing its financial results for the three and six months ended June 30, 2026. However, the actual financial and operational metrics, cash flow details, unique company-specific indicators, or any forward-looking outlook/guidance are not included within the text provided in this specific reference document.

### Related Stocks

- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)

## Related News & Research

- [First Tracks Biotherapeutics Director Sold Shares Worth Over $1.7M](https://longbridge.com/en/news/298073734.md)
- [Analyst Reiterates Buy on TRAX as IL-15/CD122 Data De-Risk Celiac Program; $57 Price Target Maintained](https://longbridge.com/en/news/297897746.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**